Matrix-Derived Nanovesicles From Healthy Porcine Tissue Reduces Liver Injury in Alcohol-Fed Mice

Alcohol-related liver disease (ALD) is characterized by hepatocellular injury, oxidative stress, inflammation, and extracellular matrix remodeling, yet effective therapies remain limited. Findings from new researchopens in new tab/window in The American Journal of Pathologyopens in new tab/window, published by Elsevier, found that a single dose of liver matrix-bound nanovesicles (MBVs) derived from healthy porcine tissue reduced liver injury, fat accumulation, and oxidative stress in alcohol-fed mice, pointing to a possible new therapeutic strategy for ALD.

MBVs are bioactive vesicles embedded within the extracellular matrix (ECM) that contribute to tissue repair and immunomodulation. While the ECM has traditionally been viewed as a passive scaffold, this new research shows it plays an active role in liver disease. This new study has found that alcohol exposure substantially changes the protein cargo carried by liver MBVs; proteins related to normal matrix structure decreased, while proteins tied to metabolic stress, detoxification, and inflammatory signaling increased.

Co-lead investigator Melanie J. Scott, MD, PhD, Department of Surgery, University of Pittsburgh, explains, “Our group's prior work showed that matrix remodeling is an early, dynamic event in ALD, often preceding fibrosis. MBVs had already been shown to carry bioactive cargo and modulate immune responses in other injury contexts, but no one had asked whether they play a role in the liver, or whether alcohol changes what they carry.”

The investigators used a mouse model of chronic-plus-binge alcohol feeding—the standard model for early alcohol-related liver injury. They isolated MBVs from the livers of alcohol-fed and control mice and used mass spectrometry to compare their protein cargo. The analysis showed that alcohol exposure produced clear changes to the protein cargo carried by liver MBVs, inducing metabolic stress and detoxification responses.

The researchers then tested whether nanovesicles from a healthy, unrelated tissue source (porcine urinary bladder matrix, already used in regenerative medicine) could counter this damage. A single injection given partway through the alcohol-feeding protocol lowered liver enzyme levels in the blood, reduced fat buildup and oxidative damage in the liver, and partially reversed the alcohol-driven changes in liver gene expression.

“Notably, this happened without suppressing neutrophil recruitment to the liver, meaning the treatment did not broadly shut down the immune response,” notes co-lead investigator Gavin Arteel, PhD, Department of Medicine and Pittsburgh Liver Research Center (PLRC), University of Pittsburgh. “Instead, it appears to work through more selective effects on metabolic and stress pathways within liver cells.”

This study is the first to characterize MBVs in liver disease and test their efficacy as a treatment. It is also a proof of concept that vesicles from a completely different tissue source, not liver-derived and not from the same species, can still produce a protective effect.

“That has implications for future development since it means a therapeutic vesicle product would not necessarily need to be liver-specific or patient-matched. This is early-stage work in mice, so it does not change clinical practice now, but it opens a new avenue for therapy development that has not been explored in this disease before,” concludes first author Yekaterina Krutsenko, PhD, Department of Medicine and Department of Surgery, University of Pittsburgh.

ALD affects a large proportion of people with chronic liver disease worldwide, accounting for nearly half of all cirrhosis cases in the United States. It is characterized by hepatocellular injury, oxidative stress, inflammation, and extracellular matrix remodeling, and treatment options remain limited. Most current approaches focus on abstinence or managing downstream damage. There is no approved therapy that directly targets the underlying injury process.

Notes for editors

The article is “Characterization and Therapeutic Application of Matrix-Bound Nanovesicles in Alcohol-Related Liver Disease,” by Yekaterina Krutsenko, Bashar Al Matour, Jiang Li, Jia-Jun Liu, Lorien Walker, Sam Taborski, Michael Merchant, Silvia Liu, George Hussey, Stephen Badylak, Gavin Arteel, and Melanie J. Scott (https://doi.org/10.1016/j.ajpath.2026.06.009opens in new tab/window). It appears in The American Journal of Pathology, volume 196, issue 11 (November 2026), published by Elsevier.

The article is openly available for 90 days at https://ajp.amjpathol.org/article/S0002-9440(26)00200-2/fulltextopens in new tab/window.

Full text of the article is also available to credentialed journalists upon request. Contact Eileen Leahy at +1 732 406 1313 or [email protected]opens in new tab/window to request a PDF of the article or more information. To reach the study’s authors, contact Melanie J. Scott, MD, PhD, at [email protected]opens in new tab/window.

This study was supported by NIH grants R01-AA030007, P30 DK120531 (Pittsburgh Liver Research Center), and S10OD028483 (University of Pittsburgh Center for Research Computing).

About The American Journal of Pathology

The American Journal of Pathologyopens in new tab/window, official journal of the American Society for Investigative Pathologyopens in new tab/window, published by Elsevier, seeks high-quality original research reports, reviews, and commentaries related to the molecular and cellular basis of disease. The editors will consider basic, translational, and clinical investigations that directly address mechanisms of pathogenesis or provide a foundation for future mechanistic inquiries. Examples of such foundational investigations include data mining, identification of biomarkers, molecular pathology, and discovery research. High priority is given to studies of human disease and relevant experimental models using molecular, cellular, and organismal approaches. ajp.amjpathol.orgopens in new tab/window

About Elsevier

Elsevier is a global leader in advanced information and decision support. For over a century, we have been helping advance science and healthcare to advance human progress. We support academic and corporate research communities, doctors, nurses, future healthcare professionals, and educators across 170 countries in their vital work. We help impact makers achieve better outcomes with research and clinical-grade solutions built on the world’s leading evidence-based scientific and medical content, precision AI, and expert human assessment. We champion inclusion and sustainability, working with the communities that we serve. The Elsevier Foundationopens in new tab/window supports research and health partnerships around the world.

Elsevier is part of RELXopens in new tab/window, a global provider of information-based analytics and decision tools for professional and business customers. For more information, visit www.elsevier.com and follow us on social media @elsevierconnect.